JP2025508779A5 - - Google Patents
Info
- Publication number
- JP2025508779A5 JP2025508779A5 JP2024549466A JP2024549466A JP2025508779A5 JP 2025508779 A5 JP2025508779 A5 JP 2025508779A5 JP 2024549466 A JP2024549466 A JP 2024549466A JP 2024549466 A JP2024549466 A JP 2024549466A JP 2025508779 A5 JP2025508779 A5 JP 2025508779A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210172397 | 2022-02-24 | ||
| CN202210172397.7 | 2022-02-24 | ||
| CN202210916833.7 | 2022-08-01 | ||
| CN202210916833 | 2022-08-01 | ||
| CN202211183393.5 | 2022-09-27 | ||
| CN202211183393 | 2022-09-27 | ||
| PCT/CN2023/078127 WO2023160651A1 (zh) | 2022-02-24 | 2023-02-24 | 一种抗体及其药物偶联物和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508779A JP2025508779A (ja) | 2025-04-10 |
| JP2025508779A5 true JP2025508779A5 (enExample) | 2026-03-02 |
Family
ID=87764835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024549466A Pending JP2025508779A (ja) | 2022-02-24 | 2023-02-24 | 抗体及びその薬物コンジュゲート並びに用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250333541A1 (enExample) |
| EP (1) | EP4484446A1 (enExample) |
| JP (1) | JP2025508779A (enExample) |
| KR (1) | KR20240150773A (enExample) |
| CN (1) | CN118786146B (enExample) |
| AU (1) | AU2023225240A1 (enExample) |
| CA (1) | CA3244292A1 (enExample) |
| WO (1) | WO2023160651A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202600596A (zh) * | 2024-03-04 | 2026-01-01 | 大陸商杭州中美華東製藥有限公司 | 抗ＦＧＦＲ２ｂ抗體、其抗體藥物偶聯物及其用途 |
| TW202543685A (zh) * | 2024-03-04 | 2025-11-16 | 大陸商蘇州宜聯生物醫藥有限公司 | 抗體藥物偶聯物及其製備方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| CN111727075B (zh) * | 2017-11-27 | 2024-04-05 | 普渡制药公司 | 靶向人组织因子的人源化抗体 |
| KR20240134250A (ko) * | 2018-01-04 | 2024-09-06 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| CN111936169A (zh) | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| CN110575547B (zh) * | 2018-06-07 | 2021-07-30 | 中国科学院上海药物研究所 | 靶向于tf的抗体-药物偶联物及其制法和用途 |
| PE20221004A1 (es) * | 2019-07-03 | 2022-06-15 | Iconic Therapeutics Inc | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados |
| EP4178608A4 (en) * | 2020-07-10 | 2024-07-24 | Iconic Therapeutics LLC | TREATMENT OF INFLAMMATORY DISEASES USING ANTI-TISSUE FACTOR ANTIBODIES |
| EP4190812A4 (en) * | 2020-07-27 | 2024-09-04 | Tuojie Biotech (Shanghai) Co., Ltd. | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS PHARMACEUTICAL USE |
| CN120093941A (zh) | 2021-02-09 | 2025-06-06 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
-
2023
- 2023-02-24 KR KR1020247029450A patent/KR20240150773A/ko active Pending
- 2023-02-24 JP JP2024549466A patent/JP2025508779A/ja active Pending
- 2023-02-24 WO PCT/CN2023/078127 patent/WO2023160651A1/zh not_active Ceased
- 2023-02-24 EP EP23759273.8A patent/EP4484446A1/en active Pending
- 2023-02-24 AU AU2023225240A patent/AU2023225240A1/en active Pending
- 2023-02-24 US US18/841,222 patent/US20250333541A1/en active Pending
- 2023-02-24 CN CN202380023138.0A patent/CN118786146B/zh active Active
- 2023-02-24 CA CA3244292A patent/CA3244292A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024535637A5 (enExample) | ||
| US20240409628A1 (en) | Antibody, antibody-drug conjugate thereof and use thereof | |
| JP6861777B2 (ja) | 抗ｈｅｒ２抗体−薬物コンジュゲート | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| JP2025138756A (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート | |
| CA2946796C (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| TWI826828B (zh) | 抗her3抗體-藥物結合物及含有其之醫藥及醫藥組成物 | |
| ES2795818T3 (es) | Anticuerpos CD48 y conjugados de los mismos | |
| JP2025508009A5 (enExample) | ||
| CN117946278A (zh) | 多特异性抗体及其制备和使用方法 | |
| TW202417508A (zh) | 抗trop2/egfr抗體及其用途 | |
| CN118873678A (zh) | 抗体偶联药物及其用途 | |
| AU2022316425A1 (en) | Drug conjugate of eribulin derivative | |
| WO2024235135A1 (zh) | 大环化合物及其制备方法和用途 | |
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| JP2025533983A (ja) | リンカー－ペイロード化合物、複合体、及びその用途 | |
| KR20240150781A (ko) | B7-h4 항체 약물 접합체를 포함하는 암 치료를 위한 병용요법 | |
| CA3244292A1 (en) | ANTIBODIES, DRUG CONJUGATES AND THEIR USES | |
| JP7861240B1 (ja) | タンパク質チロシンキナーゼ７抗体及び抗体－薬物コンジュゲート | |
| RU2025101032A (ru) | Слитый белок, содержащий антитело против cd73 и il-2, и его применение | |
| WO2025106658A1 (en) | 5t4 antibody drug conjugates and methods of their use | |
| WO2025056748A1 (en) | Antibody-drug conjugate | |
| WO2024235131A1 (zh) | 大环类药物偶联物及其制备方法和用途 | |
| CN118804928A (zh) | 用于与pd-1x ctla-4双特异性分子组合使用b7-h3抗体-药物缀合物的方法 | |
| EA051050B1 (ru) | Конъюгат лекарственного средства производного эрибулина |